Iterum Therapeutics PLC expected to post a loss of 14 cents a share - Earnings Preview

Iterum Therapeutics

09/05/2025 16:15

Iterum Therapeutics PLC ITRM.OQ ITRM.O is expected to report results on May 13 for the period ending March 31 2025

​LSEG's mean analyst estimate for Iterum Therapeutics PLC is for a loss of 14 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Iterum Therapeutics PLC is $7.00​, above​ its last closing price of $1.05. ​​​

This summary was machine generated May 9 at 15:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)